Standout Papers

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors 2011 2026 2016 2021 1.8k
  1. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors (2011)
    Éric Raymond, Laëtitia Dahan et al. New England Journal of Medicine
  2. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial (2014)
    Sung Hoon Noh, Sook Ryun Park et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 77 standout
Sub-graph 1 of 19

Citing Papers

Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Targeting angiogenesis in oncology, ophthalmology and beyond
2023 Standout
17 intermediate papers

Works of Jen‐Shi Chen being referenced

Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.
2023
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Jen‐Shi Chen 3495 1868 1175 1710 242 6.4k
Lene Mellemkjær 2541 1446 922 2449 202 11.1k
Mark F. Munsell 3527 2191 969 1446 238 11.5k
Emanuela Scarpi 3391 1804 1336 725 260 6.9k
Paul F. Engstrom 3482 1369 446 977 121 7.0k
Þorvarður R. Hálfdánarson 4124 940 191 3033 258 6.1k
Rebecca Wong 3586 3957 743 975 290 9.8k
Jordan M. Cloyd 3283 1726 462 1104 325 6.4k
Karen H. Antman 3425 3227 608 544 144 8.3k
S. Monfardini 4885 2844 720 998 339 10.4k
Young‐Joo Won 4290 3093 731 1787 163 10.0k

All Works

Loading papers...

Rankless by CCL
2026